Hot Life Science Investor Mandate 1: Billion Dollar China VC Seeks Novel Medical Devices & Reformulated Drug Opportunities

3 Dec

A venture capital firm with offices throughout China manages about USD 1 billion in committed capital with three USD funds and three RMB funds. The firm typically invests in series A and B rounds. The firm can invest anywhere from a few hundred thousand dollars up to ten million or more over a 10 year horizon. At present, the firm is looking for new investment opportunities in Greater China, while it also considers US- or EU-based companies that are Chinese-led or have a China angle.

The firm seeks to invest in a broad array of technologies including therapeutics, medical devices, IVD, healthcare big data and mHealth. Within therapeutics, the firm is interested in reformulated and generic drugs. The firm typically does not consider novel drugs. Within medical devices, the firm is interested in disposable devices and products that address large unmet medical need in China. The firm is opportunistic in terms of subsectors and stage of development. Historically, the firm invested in radiology imaging, clinical cell and molecular genetics testing, POC devices, mobile health, diagnostics and genomics, and drug discovery.

The firm is looking for competent and experienced management teams. The firm typically seeks a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: